Compositions and methods for modulating complement factor B expression
Thazha P. Prakash, Carlsbad, CA (US); Punit P. Seth, Carlsbad, CA (US); Eric E. Swayze, Encinitas, CA (US); Tamar R. Grossman, La Jolla, CA (US); Michael L. McCaleb, La Jolla, CA (US); Andrew T. Watt, San Diego, CA (US); and Susan M. Freier, San Diego, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed on May 7, 2021, as Appl. No. 17/314,537.
Application 16/357,018 is a division of application No. 15/307,526, granted, now 10,280,423, issued on May 7, 2019, previously published as PCT/US2015/028916, filed on May 1, 2015.
Application 17/314,537 is a continuation of application No. 16/357,018, filed on Mar. 18, 2019, abandoned.
Claims priority of provisional application 62/076,273, filed on Nov. 6, 2014.
Claims priority of provisional application 61/987,471, filed on May 1, 2014.
Prior Publication US 2023/0057718 A1, Feb. 23, 2023
1. A modified single-stranded oligonucleotide covalently attached to a conjugate group, wherein the modified single-stranded oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 8 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 455, and wherein the conjugate group covalently attached to the modified single-stranded oligonucleotide comprises:
